In the sub-sectors of the entire pharmaceutical sector, the policy is disturbed, and the period of change is about to be brought about. The market's sentiment towards the pharmaceutical sector continues to fall, and the valuation center basically bottoms out. In the absence of a favorable policy environment, we believe that the future will still be at the bottom. However, the recent international journal PeerJ published online research by Ma Zhanshan, a researcher at the Kunming Institute of Zoology, Chinese Academy of Sciences, and Dr. Ye Chengyu from the University of Maryland, USA. In the field of gene sequencing , another important breakthrough was made. The new algorithm reduced the error rate of three generations of sequencing to less than 0.5%. Conducive to the large-scale commercial promotion of the third-generation sequencer, the clinical application in the field of sequencing is expected to further differentiate. This breakthrough stimulates the sharp rise of the precision medical sector in the secondary market. The related concept stocks such as Anke Bio and Daan Gene are up and down, and sequencing is used as precision medicine . The basic link will drive the entire industry forward, and the entire precision medical sector will resurface. We have been one of the most closely watched sellers in the precision medical industry in the market. We have held salons in Shanghai and Shenzhen on topics such as precision treatment and precision diagnosis. We believe that precision medicine is a topical sector with long-term growth and unrelenting investment. In the risk appetite rebound, there are better investment opportunities, the recommended targets: Livzon Group, Beilu Pharmaceutical, Daan Gene. Focus on the industry: In order to implement the Regulations on Vaccine Circulation and Vaccination Management, regulate the circulation of vaccines and vaccination management in China, and effectively protect the health rights and interests of the broad masses of the people, the CFDA and the Health Planning Commission will regulate the relevant content requirements. After the implementation of the regulations, the domestic vaccine industry has undergone major changes. In the future, there will be no more vaccine enterprises, which will be simplified into two main bodies of production and entrusted distribution enterprises. The key lies in the construction of cold chain transportation. We believe that the cost of self-built cold chain of vaccine enterprises is too high. There is a high possibility of entrusting enterprises to distribute goods. Among them, cold chain drug circulation enterprises may benefit from it. It is recommended to pay attention to Shanghai Pharmaceutical, Jiuzhoutong and Sinopharm, which have perfect circulation chain transportation and warehousing. Long-term investment perspective: It is recommended to pay attention to two main lines: 1> pharmaceutical companies with variety advantages, sales advantages, and resource integration capabilities, such as Tasly, Hengrui Medicine, Huahai Pharmaceutical, Livzon Group, Kunming Pharmaceutical Group, etc.; 2> Diagnosis and treatment methods In the big data era, product and business model innovation and private capital enter the medical service field to bring investment opportunities to the pharmaceutical and medical industries , related to genetic sequencing, cell therapy, mobile medical , wearable medical equipment and medical services stocks, related See the text for the subject. Market performance: From the beginning of 2015 to the current pharmaceutical sector analysis, the pharmaceutical sector absolute yield of 25.0%, the same period of Shanghai and Shenzhen 300 absolute yield of -12%, the pharmaceutical sector outperformed the Shanghai and Shenzhen 300 about 37 percentage points. This week, the pharmaceutical sector fell 0.9%, the sub-sectors all fell, and the pharmaceutical business sub-sector fell by 2.30%. Based on the TTM overall valuation, the current pharmaceutical sector valuation is 38 times PE, which is greater than the historical average (37 times PE), and the premium rate relative to all A shares (excluding the financial sector) remains at 26%. Chinese herbal medicine prices: Chengdu Chinese herbal medicines price index fell slightly. Forest Fire Suit,Fire Entry Suit,Wildland Firefighter Gear,Heat Resistant Suit,bee-proof clothing joho(HK) Technology Co. , Ltd. , https://www.joho-safety.com